Quick Answer
Apimeds Pharmaceuticals US, Inc. reported Earnings Per Share Diluted of $0.18 (loss) per share for the year ending 2024.
- Apimeds Pharmaceuticals US, Inc. showed a decrease of -5.9% in Earnings Per Share Diluted from 2023 to 2024.
- This data is from Apimeds Pharmaceuticals US, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2023 to 2024 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $0.04 (loss) per share | Q2 2024: $0.06 (loss) per share | Q3 2024: $0.04 (loss) per share | Q1 2025: $0.05 (loss) per share | Q2 2025: $0.26 (loss) per share | Q3 2025: $0.14 (loss) per share.
- Historical annual values: Fiscal year 2024: $0.18 (loss) per share | Fiscal year 2023: $0.17 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: